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Dendritic cells (DCs) play a central role in shaping immunogenic as well as tolerogenic adaptive immune responses and thereby dictate the outcome of adaptive immunity. Here, we report the generation of a CD8α
+ DC line constitutively secreting the tolerogenic cytokine interleukin (IL)-35. IL-35 secretion led to impaired CD4 + and CD8 + T lymphocyte proliferation and interfered with their function in vitro and also in vivo. IL-35 was furthermore found to induce a tolerogenic phenotype on CD8α + DCs, characterized by the upregulation of CD11b, downregulation of MHC class II, a reduced costimulatory potential as well as production of the immunomodulatory molecule IL-10. Vaccination of mice with IL-35-expressing DCs promoted tumor growth and reduced the severity of autoimmune encephalitis not only in a preventive but also after induction of encephalitogenic T cells. The reduction in experimental autoimmune encephalitis severity was significantly more pronounced when antigen-pulsed IL-35 + DCs were used. These findings suggest a new, indirect effector mechanism by which IL-35-responding antigen-presenting cells contribute to immune tolerance. Furthermore, IL-35-transfected DCs may be a promising approach for immunotherapy in the context of autoimmune diseases.
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The immune system has to cope simultaneously with foreign substances while maintaining tolerance to self-antigens. Dendritic cells (DCs) play a dual role in linking and integrating innate and adaptive immune responses. Due to their central role, DCs are particularly interesting targets for novel immunotherapeutic approaches for the specific treatment of autoimmune diseases.
Interleukin (IL)-35 is a heterodimeric protein composed of a P35 (Il12a) and an Ebi3 (Il27b) chain. IL-35 is described to be produced predominantly by natural regulatory T (Treg) as well as CD138 + plasma cells (1, 2) . Administration or over-expression of IL-35 has been shown to confer protection to the development of various experimental autoimmune diseases through the suppression of CD4 + T cell proliferation and function. IL-35 furthermore induces a distinct subset of Foxp3 − Treg (iTr35) and B cells (1, 2) . More recently, IL-35 has been shown to be involved in the maintenance of tolerance in the intestinal tract (1, 3) . In addition, EBI3, but not IL-27p28, is expressed in different human cancers like Hodgkin lymphoma or nasopharyngeal carcinoma cells (4, 5) . IL-35 production has not only been implicated in neoplastic but also in tumor-associated cells, suggesting a more diverse production and function than initially proposed (6, 7) . Despite these recent insights, the biological relevance for immunoregulation as well as the exact function of the cytokine IL-35, especially on non-lymphoid cells, remains elusive. We previously described a stable CD8α + DC line [murine tumor DC line (MuTu DC)] (8, 9) . This cell line exhibits phenotypical and functional characteristics of freshly isolated CD8α + DCs, i.e., expression pattern of surface markers, potent costimulation, cross-presentation of antigens, and induction of cytotoxic responses by CD8 + T lymphocytes (9) . MuTu DCs can easily be cultured for over a time span of around 40 passages in vitro. The MuTu DCs exhibit an immature phenotype with low expression of costimulatory molecules, which can be upregulated upon activation with toll-like receptor ligands. Intravenously injected MuTu DCs accumulate primarily in liver and spleen. They are, however, rejected in a CD8
+ T cell-dependent manner within 5 days after transfer. By contrast, adoptive transfer into rag-deficient or SV40lgT transgene tolerant mice as well as into wild-type mice depleted of CD8 T cells leads to development of MuTu DC tumors within 1 month (10) . The MuTu cell line allowed us to investigate the tolerogenic potential of DCs in a rational and standardized way. Our results demonstrate that the expression of IL-35 potently regulates CD4
+ as well as CD8 + T cell responses in vitro and also in in vivo. We could further show that CD8α
+ DCs respond to IL-35 signaling by acquiring a tolerogenic phenotype. Antigen pulsing of the IL-35-expressing MuTu DC line was further shown to ameliorate autoimmune encephalitis in a preventive as well as in a therapeutic setting. Our experiments indicate this effect to be, at least partially, dependent on interactions with IL-35-conditioned DCs. These findings suggest a novel, indirect mechanism by which IL-35 modulates adaptive immune responses.
aniMals anD MeThODs

Mice
C57BL/6, BALB/c, and RAG1
−/− C57BL/6 mice were purchased from Harlan laboratories. OT-I and OT-II transgenic mice were maintained and bred in our own facility. All animals were kept and bred in a specific pathogen free animal facility. For all experiments, female, age-matched (6-8 weeks) mice were used. All animal experiments were performed after approval by the cantonal veterinary office (Service de la consommation et des affaires vétérinaires, Département du territoire et de l' environnement, Permission no. VD2490.1).
generation of il-35
+ MuTu Dc line 20) and the cells maintained in vitro for maximally 15 passages. Transgene expression was confirmed after each transduction by RT-PCR using the following primers: Ebi3: 5′-ATGTCCAAGCTGCTCTTCCT-3′ (forward), 5′-AGAGGAGTCCAGGAGCAGTC-3′(reverse). P35: 5′-AAA TGAAGCTCTGCATCCTGC-3′(forward), 5′-TCACCCTGTTG ATGGTCACG-3′ (reverse). All MuTu DC lines were cultured in IMDM-Glutamax (GIBCO) supplemented with 10% heatinactivated fetal calf serum, 10 mM HEPES (GIBCO), 50 µM β-mercaptoethanol (GIBCO), 50 U/ml of penicillin, and 10 µg/ml streptomycin (GIBCO) at 37°C in 5% CO2 atmosphere.
il-35 immunoprecipitation
Interleukin-35 was precipitated from cell lysate using IL-12p35-specific antibodies (R&D systems, clone #45806) and protein A/G beads (Santa Cruz Biotechnology). Western blotting was conducted as described previously. In brief, cell lysates were centrifuged at 12,000 rpm for 30 min at 4°C. Protein concentrations of cell lysates were determined with the BCA assay (Pierce) and 40 µg of proteins were loaded onto 7.5-15% SDS-polyacrylamide gels. The gels were transferred to nitrocellulose membrane (Amersham Pharmacia Biotech). The blot was blocked in blocking buffer (5% non-fat dry milk/1% Tween 20 in PBS) for 2 h at room temperature and then incubated with Ebi3-specific antibody (Shenandoah Biotechnology, clone V1.4H6.29) in TBST overnight at 4°C. The blot was incubated with HRP-coupled secondary antibody for 2 h at room temperature. Blot was visualized by ECL (Pierce Biotechnology).
T cell Proliferation assays
Mixed Leukocyte Reaction (MLR)
BALB/c responder cells were isolated from spleen and popliteal lymph nodes using 40-µm cell strainer. CD4
+ and CD8 + T cells were purified by immunomagnetic bead-based sorting following protocol supplied by the manufacturer (Miltenyi Biotec). Then, 1 × 10 5 responder T cells were stained with 5 µM efluor670 proliferation dye (eBioscience) and cocultivated with either control DCs, IL-35 + DCs, or syngeneic CD4 + or CD8 + depleted splenocytes at different ratios in 96-well U-bottom plates. T cell proliferation and activation were assessed after 3 days by flow cytometry and IL-35 mRNA expression was measured by RT-PCR.
iTreg Suppression Assay
Suppression assays were performed as described by Collison and Vignali (11) with CpG and polyI:C for 6 h. CD4 + T cells were magnetically isolated from C57BL/6 mice using the naïve CD4 + T cell isolation kit (Miltenyi) and plated at a 10:1 (1 × 10 6 cells) ratio to mock or IL-35 + DCs. A 2 ng/ml recombinant TGF-β and a 10 ng/ml IL-2 were added to some of the wells containing mock DCs for the generation of Foxp3 + Tregs. Cells were incubated for 4 days. Different amounts of the generated suppressor T cells were then seeded with 2.5 × 10 4 efluor670 proliferation dye stained naïve target CD4 + T cells. Proliferation of the target cells was assayed after 3 days. Percent suppression was calculated using the following formula: % % proliferated Tconv alone proliferated Tconv − treated with Treg proliferated Tconv alon % e e ×100.
In Vitro OT-I/II Proliferation 
In Vivo OT-I/II Proliferation
CD8
+ or CD4 + T cells were magnetically isolated from CD45.1 + OT-I/Rag −/− or OT-II mice, respectively and stained with 5 µM efluor670 proliferation dye (eBioscience). The 2 × 10 5 T cells were intravenously injected into CD45.2 C57BL/6 mice. Then, 2.5 × 10 6 cells of the respective CD8α + DC line were pulsed with either SIINFEKL (OT-I restricted, 1 µg/ml) or OVA329-337 (OT-II restricted, 50 µM) peptide and were i.v. injected on the same day and 1 day after T cell transfer. Mice were sacrificed 4 days later and the isolated splenocytes were analyzed by flow cytometry.
Tumor experiments
B16.F0 melanoma and CMT93 colon carcinoma tumor cell lines were cultured in DMEM medium (GIBCO), supplemented with 10% FCS, and 50 U/ml of penicillin and 50 mg/ ml streptomycin (GIBCO). Tumor cell lysate was generated by five consecutive freeze/thaw cycles in liquid nitrogen. Lysate was centrifuged at 1500 g for 15 min before use. Mock-or IL-35-transduced DCs were pulsed with respective lysate in a 1:4 lysate to DC ratio and 100 U/ml IFN-γ (eBioscience). Five and three days before and three days after tumor cell transfer, 2.5 × 10 6 DCs were s.c. injected in the flank. Tumor was induced by s.c. injection of 2 × 10 5 B16.F0 or 2 × 10 6 CMT93 cells into the same flank. Tumor growth was followed by measuring length and width using a caliper. Tumor volume was measured using the formula V = ⋅ ⋅ ⋅ ( ) π 6 1 58 3 2 . length width as described by
Wurzenberger et al. (12) .
Flow cytometry
The fluorochrome-conjugated antibodies used were specific to CD11c (clone N418, PECy7), GR1 (clone RB6-8C5, PE, or induction of adoptive Transfer experimental autoimmune encephalitis (eae)
Adoptive transfer EAE was induced as described by Miller and Karpus (13) . Briefly, myelin oligodendrocyte glycoprotein (MOG) reactive T cells were primed in donor C57BL/6 mice by two subcutaneous injections of MOG35-55-peptide emulsified in complete Freud's Adjuvant (Sigma). Intraperitoneal injection of 200 ng Pertussis Toxin (Sigma) was used to boost lymphocyte priming. In order to study the effect of tolerogenic molecules, MOG35-55 peptide-pulsed DCs were intravenously injected 1 day before and 1 day after the immunization. Twelve days post immunization, inguinal, brachial, and axillary lymph nodes were isolated by digestion in 1 mg/ml Collagenase D (Roche) for 20 min at 37°C. Single cells suspension was prepared using a 40-µm cell strainer (Falcon). Lymph node cells were expanded in vitro for 3 days in the presence of MOG35-55-pulsed DCs and 0.5 ng/ml recombinant IL-12p70 (eBioscience). Then, 5 × 10 6 MOG-specific T cells were then transferred to C57BL/6 recipient mice by i.p. injection. Mice were i.v. injected with MOG35-55-pulsed DCs 1 day after T cell transfer. Clinical EAE symptoms were scored daily in a blinded manner: 0-no obvious changes in motor functions; 1-decreased tail tonus; 2-abnormal gait (ataxia and/or impaired righting reflex); 3-partial hind limb paralysis; 4-complete hind limb paralysis; and 5-complete hind and fore limb paralysis.
gene expression analysis by real-time Pcr
Total RNA was isolated from the cells and purified using the RNeasy ® spin columns following the manufacturer's protocol (Qiagen). Total RNA yields were quantified by Nanodrop spectrophotometry (Thermo Fisher Scientific). Synthesis of cDNA was performed using random nonamer primers and the Superscript II Reverse Transcriptase kit (Invitrogen). cDNA was purified using the PCR clean-up kit (Qiagen) and stored at −80°C.
Real-time PCR (RT-PCR) was performed in technical triplicates using SYBR FAST qPCR mix (KapaBiosystems) and 5 ng RNA/reaction on a LightCycler480 machine (Roche Diagnostics). Relative expression levels were analyzed using qBase+ 1.2 data analysis software (BioGazelle). Gene expression for each individual sample was normalized to the housekeeping genes HPRT 5′-AGCCTAAGATGAGCGCC-3′ (forward) and 5′-TTACTAGGCAGATGGCCACA-3′ (reverse) and β-actin 5′-GCACAGCTTCTTTGCAGCTCCTTCG-3′ (forward) and 5′-TTTGCACATGCCGGAGCCGTTG-3′ (reverse).
statistical analysis
Differences between groups were determined using either unpaired two-tailed Student's t-test or Mann-Whitney U test where indicated. All statistical analyses were performed using Prism 6.0 (GraphPad). p-Values are indicated when considered statistically significant (*p ≤ 0.05, **p ≤ 0.005, ***p ≤ 0.001). Figure 1A) was generated by lentiviral transduction of the recently established CD8α + MuTu DC line (thereafter named "wtDC") (9) . Il12p35 and Ebi3 transcripts were detected via quantitative PCR (Supplementary Figure 1B) . Ebi3 protein expression was confirmed by western blot of the cell lysate of cultured IL-35-expressing DCs after immunoprecipitation using anti-IL-12p35 antibody (Supplementary Figure 1C) . For the remainder of this manuscript, the IL-35-expressing MuTu DC line is referred to as "IL-35 + DC. " Additionally, empty vector-transduced DCs (mock DCs) were generated and used as controls when appropriate. We could not observe any noticeable differences in the morphological characteristics or the proliferative capacity when comparing the wtDC line to the lentivirally transduced MuTu DC lines. costimulatory molecules CD40 and CD86 ( Figure 1B) . Activation of the control DCs with TLR3 and TLR9 ligands polyI:C and CpG led to increased surface expression of MHC II as well as costimulatory receptors CD40, CD80, and CD86 by control DCs. Conversely, IL-35 + DCs exhibited a complete unresponsiveness to TLR stimulation as indicated by the failure to upregulate any of the analyzed (co-)stimulatory molecules. Interestingly, IL-35 + DCs showed an increased CD80 expression already under resting condition when compared to mock DCs. A more than twofold reduction in IL-12p40 secretion could be detected by ELISA in the culture medium of IL-35 + DCs while the production of the immunoregulatory cytokine IL-10 was found to be increased significantly ( Figure 1C) .
In order to investigate whether the observed phenotypic change of IL-35 + DCs is provoked by an autocrine effect of the transgene, wild-type MuTu DCs were cultured for 4 days in IL-35 containing culture medium. As observed for IL-35-transduced MuTu DCs, IL-35-conditioned wild-type DCs expressed markedly higher levels of CD11b. On the contrary, the expression of CD11c, CD8α, and DEC205 was not significantly altered when compared to cells cultured in control medium (Figure 2A ). Upon activation with TLR3 and TLR9 ligands, IL-35-conditioned but not control DCs exhibited a significantly impaired upregulation of MHCII and the costimulatory receptor CD40. Similar to IL-35 + DCs, IL-35 conditioning increased the expression of CD80 already under steady-state conditions and TLR stimulation did not further augment its surface expression ( Figure 2B) . Moreover, upon TLR stimulation, MuTu DCs cultured in IL-35 supplemented medium secreted significantly less IL-12p40 and IL-6 cytokine when compared to DC grown in control medium. In contrast to IL-35 + DCs, no increase in IL-10 secretion could be detected ( Figure 2C ).
il-35-expressing MuTu Dcs impair T cell Proliferation and Function
We have previously demonstrated that the MuTu DC lines efficiently induce T cell proliferation in MHCI or MHCII restricted systems (9) . IL-35 on the other hand, is described to inhibit CD4 + T cell proliferation (2, 14) . We therefore tested whether the IL-35-producing DC line is able to affect T cell activation and function. An allogeneic MLR was performed using variable amounts of mock transduced or IL-35 expressing, C57BL/6-derived DCs as stimulators. Coculture with mock-transduced DCs resulted in a robust, DC number-dependent proliferation of BALB/c-derived CD4 + responder T cells. This was accompanied by an increased percentage of activated CD44 + CD62L − T cells and IFN-γ-expressing T cells. On the contrary, target cell proliferation and activation were severely reduced when IL-35 + DCs were used as activator cells (Figure 3A) . Analysis of target T cell RNA revealed a significant upregulation of IL-35-associated P35 and Ebi3, but not IL-12-or IL-27-specific P40, respectively, P28 transcripts. In contrast to IL-35 + DCs, culture with mock-transduced DC led to a significant upregulation with IL-12/23-associated P40 but not P35 or Ebi3 transcripts ( Figure 3B Figure 3A) .
OT-II T cells as well as their IFN-γ production (Supplementary
There is only limited information on the effects of IL-35 on the proliferation and effector functions of CD8 + T cells available. Allogeneic MLR-culturing BALB/c-derived CD8 + T cells with C57BL/6 IL-35 + or mock-transduced MuTu DCs were therefore performed. We found that IL-35 + but not mock DCs significantly reduced proliferation, activation status, as well as IFN-γ expression by CD8 + T lymphocytes ( Figure 3C ). IL-35 + DCs furthermore induced the transcription of significantly higher levels of Ebi3 and P35 in CD8 + T cells than mock-transduced DCs ( Figure 3D) . Similarly, a drastic reduction in the abundance of CD45.1 + CD8 + T cells could be observed upon co-injection of OT-I CD8 + T cells together with OVA323-339 peptide-pulsed IL-35-expressing but not mock-transduced DCs into C57BL/6 mice (Supplementary Figure 3B) . No differences in cell number and in IFN-γ expression of host-derived CD45.2 + CD8 + T cells were observed (Supplementary Figure 3C) .
Interleukin-35 cytokine was originally described to mediate infectious tolerance via the induction of a regulatory phenotype on naïve CD4
+ T cells (14) . We therefore tested whether the observed induction of 
il-35-conditioned MuTu Dcs impair cD4 + T cell Proliferation and Function
As demonstrated above, IL-35 + DCs as well as wild-type DCs cultured in IL-35 containing medium did not adequately upregulate MHCII and costimulatory receptors upon activation, but remained in a rather immature state with increased CD80 expression. Such immature DC populations have been described to induce and maintain T cell tolerance (15) . We therefore considered the possibility that the observed effects on T cells were not only caused directly by the secreted IL-35, but indirectly 
Vaccination with il-35 + Dcs Promotes Tumor growth
Interleukin-35 has been shown to promote tumor progression by interfering with tumor-directed immune responses in several human cancers (6, 16, 17) . In order to determine whether IL-35 Figure 6D) .
Similarly, subcutaneously transferred CMT93 carcinoma cells showed progressive tumor growth in IL-35 + DC-vaccinated mice and tumor volume was significantly bigger when compared to control animals (Supplementary Figure 4A) . In accordance to our observations in the B16. Figure 4B) .
Transfer of il-35 + MuTu Dcs interferes with Development of eae
In order to assess the potential of IL-35 + DCs to abrogate autoimmune T cell activity in vivo, adoptive transfer EAE was induced as described in Section "Animals and Methods. " Adoptive transfer allowed us to introduce IL-35 + DCs into the experimental system either already during priming of the encephalitogenic lymphocytes (experimental groups 2 + 3) or only in already diseased recipient mice (experimental groups 
IL-35
+ DCs (experimental group 2) exhibited a less activated phenotype and produced less IFN-γ than T cells restimulated in the presence of MOG35-55-pulsed mock DCs (experimental group 1) (Figure 7B) . After in vitro restimulation, 5 × 10 6 T cells were transferred into wild-type C57BL/6 mice. The animals were surveilled daily for the development of EAE-related symptoms. Recipient mice receiving MOG35-55 reactive T cells that were primed in the presence of mock DCs (experimental group 1) reproducibly exhibited EAE symptoms within 9 days after T cell transfer. A maximum disease score of three, corresponding to a complete paralysis of the hind limbs, could be observed between 14 and 18 days after T cell transfer. The animals subsequently recovered and no disease symptoms could be observed 25 days after the transfer of immunogenic T cells. By contrast, mice that received T cells primed and restimulated in the presence of MOG35-55 peptide loaded IL-35 + DCs exhibited a drastically reduced disease severity (experimental group 2). Animals injected with unpulsed IL-35 + DCs (experimental group 3) exhibited an intermediate disease course: EAE symptoms were less vigorous when compared to the mock DC control group but were significantly more severe than in MOG35-55-pulsed IL-35 + DC injected mice ( Figure 7C) . We further assayed whether the therapeutic transfer of IL-35 + DCs is sufficient to limit the function of MOG-primed lymphocytes. Both, in vitro restimulation with MOG35-55-pulsed IL-35 + DCs (experimental group 4) or the injection of IL-35 + DCs into recipient animals 6 and 8 days after the transfer of MOG-primed T cells (experimental group 5) slightly delayed the disease onset and led to a significant reduction of EAE symptoms.
The brains were collected at the peak of disease. Histological analysis of sections of the cerebral cortex revealed focal inflammatory lesions within the myelin rich regions with a preferential perivascular accumulation of CD3 + cells in diseased control animals. No formation of such lesions, but only few isolated T cells could be observed in the IL-35 experimental group (Figure 7D) .
DiscUssiOn
Due to their central role in determining the outcome and quality of adaptive immune responses, DCs are of special interest as potential therapeutic tools for the specific treatment of autoimmune disease. In contrast to the other members of the IL-12 cytokine family, IL-35 has been described to inhibit T and B lymphocyte proliferation and induce Foxp3 − , IL-35-secreting Treg cells (iTr35) (14) . Recent studies indicate that IL-35 also regulates effector functions of plasma cells as well as monocyte-derived DCs (18) . Although IL-35 seems to contribute essentially to the maintenance of immune tolerance and represents a promising candidate for immunotherapy, its functionality and tolerogenic potential remain poorly investigated.
Recombinant IL-35 has a limited stability, which complicates the investigation of this cytokine (19) . We thus generated a containing medium nor IL-35-conditioned DCs alone induced the transcription of IL-35 subunits by CD4 + T cells. Moreover, in the absence of (co-)stimulation, IL-35-conditioned T cells were not capable to suppress naïve target T cell proliferation. These results suggest that IL-35 cytokine secretion alone is sufficient to regulate T cell proliferation and function. However, the induction of IL-35-expressing iTr35 cells depends on both, TLR stimulation and additional stimuli provided by DCs. Others have consistently reported that the generation of functional iTr35 is dependent on CD3/CD28-mediated activation (14, 21) . Furthermore, CD80/CD86 expression by DCs is necessary for the maintenance of Treg cells (22) . In the context of IL-35-mediated propagation of immune tolerance, IL-35-conditioned DCs might exert a similar function on Treg cells. We indeed observed a consistent upregulation of CD80 when DCs were conditioned with IL-35. CD80 upregulation was consistently observed, even when DCs were not stimulated by TLR ligands. We thus suggest that IL-35 contributes to a semi-mature, tolerogenic DC (tolDC) phenotype. Low level of antigen presentation, the increase in CD80 expression, together with the expression of IL-10 might be involved in the generation of iTr35 cells. We have shown in this manuscript that IL-35-conditioned DCs acquire tolerogenic functions even when IL-35 is removed but without IL-35 they cannot induce IL-35 expression in responding T cells. However, the molecular basis for this regulatory circuit has yet to be elucidated.
Immature or induced tolDCs play an essential role in the maintenance of peripheral tolerance by modulating T cell activation and inducing Tregs (23) . Several mediators like IL-10 or vitamin D3 have been demonstrated to induce a tolerogenic phenotype on DCs. tolDCs are characterized by low levels of MHCII and costimulatory markers, as well as a reduced secretion of pro-inflammatory cytokines while expressing tolerogenic molecules such as IL-10 or IDO. In addition, the expression of CD11b has been associated with a tolDC phenotype (24, 25) . In our hands, the presence of IL-35 induced a CD11c lo CD11b hi , MHCII lo semi-mature phenotype on the MuTu DC line. The presence of IL-35 impaired their ability to upregulate the expression of MHCII and costimulatory molecules in response to stimulation with TLR ligands. TLR ligand activated IL-35 + DCs expressed the inhibitory cytokine IL-10 whereas IL-12 secretion was greatly diminished. A similar shift in cytokine production was described by others when CD4 + T cells were activated in the presence of recombinant IL-35 (26) . The incubation of TLR ligands activated DCs with IL-35 containing but not control culture medium had a similar effect on the expression levels of CD11c, CD11b, MHCII, and costimulatory receptors. These finding suggest that the IL-35 cytokine directly affects the MuTu DCs, maintaining them in a semi-mature state and rendering them unresponsive to TLR-activation. In contrast to IL-35 + DCs, no IL-10 secretion was detectable when DCs were cultured with IL-35 containing medium. This observation implies functional disparities between stably transduced and IL-35-conditioned DCs which can hardly be addressed with our current experimental setup. It is conceivable that IL-35 induced IL-10 expression requires prolonged signaling or needs to exceed a certain signal threshold. We can therefore also not completely rule out that IL-35 induces the expression of secondary, unknown mediator(s) which, in turn, drive the observed phenotypic changes of the DCs. However, a potential IL-35 receptor has been postulated to consist either of IL-12Rβ2 and IL-6 or IL-27Rα, respectively. Engagement of the receptor was demonstrated to result in the activation of STAT1-, STAT3-, or STAT4-mediated signaling in T or B cells, respectively (27, 28) . It was recently shown that IL-35 interferes with the LPS-induced activation of MAPK-AP1 pathway in mouse endothelial cells, thereby suppressing the expression of various pro-inflammatory cytokines and chemokines (29) . The potential receptor chains are expressed by CD8α + DCs as well as in most conventional DC subtypes (our unpublished data). Thus, a direct effect of IL-35 on DCs is at least possible. In addition, both, STAT3 was well as p38/ MAPK-mediated signaling, has been shown to regulate MHCII as well as costimulatory receptor expression upon DC activation. These molecular pathways therefore represent potential mediators of IL-35-induced signaling in DCs (30, 31) . Further investigation is needed to elucidate the composition and expression of the IL-35 receptors on DCs as well as the downstream signaling events driving the observed phenotypic changes in IL-35-transduced and IL-35-conditioned DCs.
The IL-35 induced tolerogenic state on wild-type DCs translated functionally into an impaired capacity to stimulate antigen-specific CD4 + and CD8 + T cell responses. As proposed for other tolDC populations, the immature phenotype is characterized by low expression of MHCII and costimulatory receptors as well as the expression of suppressive molecules like IL-10. The addition of IL-10 was described to enhance the conversion of naïve CD4 + T cells into iTr35, representing a potential mechanism by which IL-35-conditioned DCs contribute to infectious tolerance (14) . Human dexamethasoneinduced tolDCs have been described to express both IL-35 subunits and these are required to elicit their full tolerogenic potential (32). It might therefore be possible that DCs can be stimulated to produce IL-35 to contribute directly immune tolerance. However, the stimuli that trigger IL-35 production, aside from IL-35 itself, remain poorly understood. In our hands, the conditioning of MuTu DCs with IL-35 did not lead to an induction of IL-35-associated genes (unpublished observations).
In order to further study the function of the IL-35 induced tolDC phenotype, we employed the IL-35 + DC line in two, differently immunogenic tumor models. Vaccination with tumor lysate pulsed, IL-35-expressing DCs notably accelerated tumor growth. This coincided with a reduced tumor infiltration of CD4 + and CD8 + T cells and the inhibition of their effector functions. A significant acceleration of tumor growth was only observed when the IL-35 + DCs were pulsed with tumor cell lysate. These observations suggest the inhibition of T cell responses to be not only caused by the systemic delivery of IL-35 but also by the interaction of antigen-presenting tolDC and tumor-specific T cells. Tumor growth in lymphocyte deficient RAG2 −/− animals was accelerated when compared to wild-type animals both upon mock and IL-35 + DC vaccination, confirming the involvement of lymphocytes in the CMT93 cancer model. In the absence of lymphocytes, tumor lysate-pulsed IL-35 + DC vaccination surprisingly led to an even faster tumor growth (data not shown). In accordance with Wang and colleagues, this indicates that IL-35-mediated pro-tumor effect is not solely due to suppression of adaptive immunity (6) . Our observations and the EAE experiments discussed below clearly show that the effect of IL-35 is, at least partly, contact dependent. They furthermore imply that the observed effects are not merely an effect of reduced MHC class II expression.
The administration of tolerogenic cytokines is thought to re-establish antigen-specific tolerance through the prevention of autoimmune T cell reactivity and expansion of regulatory lymphocyte populations. Others have shown the treatment with recombinant IL-35 or the ectopic expression of the cytokine by different cells to protect mice against a variety of autoimmune diseases (1, 33, 34) . Furthermore, the intraperitoneal injection of IL-35 was recently shown to ameliorate autoimmune pathogenicity in a murine asthma model partly through the induction of an immune-suppressive phenotype on monocyte-derived DCs (18) . We therefore investigated whether the IL-35 + MuTu DC line might be employed to affect the development of the CNS autoimmune disease EAE. The preventive transfer IL-35 + DCs but not control DCs was found to significantly reduce EAE symptoms. The observed effect was found to be mediated through the impairment of activation and function of the transferred CD4
+ T cells, resulting in a reduction of CNS infiltration and inflammation. This can be only partially attributed to the systemic delivery of IL-35 by the IL-35 + DCs itself, as the transfer of unpulsed IL-35 + DCs indeed reduced EAE severity. However, a further, significant reduction of EAE severity was observed only upon loading the IL-35 + DCs with myelin specific peptide. These findings suggest the interaction of IL-35 + DCs and T lymphocytes to be required for an optimal suppression of autoimmunity. Thus, the IL-35 induced immature phenotype of the DCs contributes to the observed reduction of EAE severity. We therefore propose IL-35-conditioned CD8α + DCs to contribute indirectly to the IL-35-mediated regulation of adaptive immune responses via the adaption of an immature phenotype. We further sought to determine the latest time point at which the application of MOG-pulsed IL- 
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